




, and 


, or an enantiomer, a diastereomer, a stereoisomer, or a pharmaceutically acceptable salt thereof.

16. The compound of any one of claims 1-8, wherein said compound has the formula:




, an enantiomer, a diastereomer, a stereoisomer, or a pharmaceutically acceptable salt thereof.

17. The compound of any one of claims 1-8, wherein said compound has the formula:




, an enantiomer, a diastereomer, a stereoisomer, or a pharmaceutically acceptable salt thereof.


18. The compound of any one of claims 1-8, wherein said compound has the formula:


, an enantiomer, a diastereomer, a stereoisomer, or a pharmaceutically acceptable salt thereof.


19. The compound of any one of claims 1-8, wherein said compound has the formula:


, an enantiomer, a diastereomer, a stereoisomer, or a pharmaceutically acceptable salt thereof.

20. The compound of any one of claims 1-8, wherein said compound has the formula:



, an enantiomer, a diastereomer, a stereoisomer, or a pharmaceutically acceptable salt thereof.

21. The compound of any one of claims 1-8, wherein said compound has the formula:




, an enantiomer, a diastereomer, a stereoisomer, or a pharmaceutically acceptable salt thereof.

22. The compound of any one of claims 1-8, wherein said compound has the formula:




, an enantiomer, a diastereomer, a stereoisomer, or a pharmaceutically acceptable salt thereof.

23. The compound of any one of claims 1-8, wherein said compound has the formula:




, or an enantiomer, a diastereomer, a stereoisomer, or a pharmaceutically acceptable salt thereof.

24. The compound of any one of claims 1-8, wherein said compound has the formula:




, an enantiomer, a diastereomer, a stereoisomer, or a pharmaceutically acceptable salt thereof.

25. The compound of any one of claims 1-8, wherein said compound has the formula:



, an enantiomer, a diastereomer, a stereoisomer, or a pharmaceutically acceptable salt thereof.

26. A compound of Formula (X):



(X)

or an enantiomer, a diastereomer, or a stereoisomer thereof, wherein


R_{20} is independently C_{1-6} alkyl or H;

R_{21} is independently C_{1-6} alkyl or H;

X^5 and X^6 are independently CH or N; and

X^7 is Br or F.

27. The compound of claim 26 having Formula (XI):



(XI), or an enantiomer, a diastereomer, or a stereoisomer thereof.

28. A pharmaceutical composition comprising one or more compounds according to any of claims 1-25 and a pharmaceutically acceptable carrier or diluent.

29. A compound according to any one of claims 1-25 for use in therapy.

30. A method of treating fibrosis in a mammal comprising administering a therapeutically effective amount of a compound according to any one of claims 1-25 or a pharmaceutically acceptable salt thereof to the mammal in need thereof.

31. A method of treating lung fibrosis (idiopathic pulmonary fibrosis), asthma, chronic obstructive pulmonary disease (COPD), renal fibrosis, acute kidney injury, chronic kidney disease, liver fibrosis (non-alcoholic steatohepatitis), skin fibrosis, fibrosis of the gut, breast cancer, pancreatic cancer, ovarian cancer, prostate cancer, glioblastoma, bone cancer, colon cancer, bowel cancer, head and neck cancer, melanoma, multiple

myeloma, chronic lymphocytic leukemia, cancer pain, tumor metastasis, transplant organ rejection, scleroderma, ocular fibrosis, age related macular degeneration (AMD), diabetic retinopathy, collagen vascular disease, atherosclerosis, Raynaud's phenomenon, or neuropathic pain in a mammal ccomprising administering a therapeutically effective amount of a compound according to any one of claims 1-25 or a pharmaceutically acceptable salt thereof to the mammal in need thereof.